Genomic Health, Inc. (GHDX) Given Consensus Rating of “Hold” by Analysts

Shares of Genomic Health, Inc. (NASDAQ:GHDX) have earned an average recommendation of “Hold” from the twelve research firms that are covering the firm, Marketbeat.com reports. Three research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and one has given a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $32.33.

Several brokerages have weighed in on GHDX. Canaccord Genuity reissued a “buy” rating and issued a $42.00 price target on shares of Genomic Health in a report on Tuesday, January 16th. Jefferies Group reissued a “hold” rating and issued a $34.00 price target on shares of Genomic Health in a report on Friday, October 20th. Zacks Investment Research raised Genomic Health from a “sell” rating to a “hold” rating in a report on Friday, October 13th. BidaskClub raised Genomic Health from a “sell” rating to a “hold” rating in a report on Tuesday, December 19th. Finally, ValuEngine raised Genomic Health from a “sell” rating to a “hold” rating in a report on Friday, December 15th.

Genomic Health (NASDAQ GHDX) opened at $34.95 on Tuesday. Genomic Health has a 52 week low of $26.37 and a 52 week high of $37.50. The stock has a market capitalization of $1,220.00, a PE ratio of -268.85 and a beta of 0.65.

Genomic Health (NASDAQ:GHDX) last posted its earnings results on Wednesday, November 8th. The medical research company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.04. Genomic Health had a negative return on equity of 1.79% and a negative net margin of 1.30%. analysts expect that Genomic Health will post -0.08 earnings per share for the current fiscal year.

In related news, COO G Bradley Cole sold 5,000 shares of Genomic Health stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $35.51, for a total transaction of $177,550.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Kimberly J. Popovits sold 10,000 shares of Genomic Health stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $34.99, for a total value of $349,900.00. The disclosure for this sale can be found here. Insiders have sold 75,717 shares of company stock valued at $2,508,132 in the last ninety days. Corporate insiders own 46.20% of the company’s stock.

A number of hedge funds have recently made changes to their positions in GHDX. Rhumbline Advisers raised its position in Genomic Health by 5.5% during the second quarter. Rhumbline Advisers now owns 24,664 shares of the medical research company’s stock valued at $803,000 after acquiring an additional 1,296 shares in the last quarter. Bank of New York Mellon Corp raised its position in Genomic Health by 1.3% during the second quarter. Bank of New York Mellon Corp now owns 89,714 shares of the medical research company’s stock valued at $2,921,000 after acquiring an additional 1,137 shares in the last quarter. Legal & General Group Plc raised its position in Genomic Health by 11.4% during the second quarter. Legal & General Group Plc now owns 6,932 shares of the medical research company’s stock valued at $226,000 after acquiring an additional 710 shares in the last quarter. Swiss National Bank raised its position in Genomic Health by 8.7% during the second quarter. Swiss National Bank now owns 33,900 shares of the medical research company’s stock valued at $1,103,000 after acquiring an additional 2,700 shares in the last quarter. Finally, Wells Fargo & Company MN raised its position in Genomic Health by 18.2% during the second quarter. Wells Fargo & Company MN now owns 61,075 shares of the medical research company’s stock valued at $1,987,000 after acquiring an additional 9,391 shares in the last quarter. Institutional investors own 89.83% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Genomic Health, Inc. (GHDX) Given Consensus Rating of “Hold” by Analysts” was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/01/23/genomic-health-inc-ghdx-given-consensus-rating-of-hold-by-analysts.html.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Analyst Recommendations for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply